Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

dentsply sirona inc. - XRAY

XRAY

Close Chg Chg %
12.05 0.69 5.73%

Closed Market

12.74

+0.69 (5.73%)

Volume: 4.35M

Last Updated:

Jan 21, 2026, 4:00 PM EDT

Trade Now

Company Overview: dentsply sirona inc. - XRAY

XRAY Key Data

Open

$12.19

 Day Range

12.10 - 12.84

52 Week Range

9.85 - 20.60

 Market Cap

$2.40B

Shares Outstanding

199.55M

 Public Float

198.26M

Beta

1.01

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.43

Yield

531.12%

 Dividend

$0.16

EX-DIVIDEND DATE

Dec 26, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

3.78M

  

XRAY Performance

1 Week
 
 -1.31%
 
1 Month
 
 7.49%
 
3 Months
 
 -8.09%
 
1 Year
 
 -38.30%
 
5 Years
 
 -78.94%
 

XRAY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 18
Full Ratings ➔

About dentsply sirona inc. - XRAY

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment is engaged in designing, manufacturing, and selling dental technology and equipment products. The Essential Dental Solutions segment designs, manufactures, and sells value-added endodontic, restorative, and preventive consumable products. The Orthodontic and Implant Solutions segment designs, manufactures, and sells various digital implant systems and dental implant products. The Wellspect Healthcare segment designs, manufactures, and sells continence care solutions for management of both urinary and bowel dysfunction dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

XRAY At a Glance

Dentsply Sirona, Inc.
13320 Ballantyne Corporate Place
Charlotte, North Carolina 28277-3607
Phone 1-844-848-0137 Revenue 3.79B
Industry Medical Specialties Net Income -910,000,000.00
Sector Health Technology Employees 14,000
Fiscal Year-end 12 / 2025
View SEC Filings

XRAY Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.017
Price to Book Ratio 1.943
Price to Cash Flow Ratio 8.37
Enterprise Value to EBITDA 10.117
Enterprise Value to Sales 1.544
Total Debt to Enterprise Value 0.388

XRAY Efficiency

Revenue/Employee 270,928.571
Income Per Employee -65,000.00
Receivables Turnover 6.259
Total Asset Turnover 0.578

XRAY Liquidity

Current Ratio 1.099
Quick Ratio 0.744
Cash Ratio 0.171

XRAY Profitability

Gross Margin 51.885
Operating Margin 6.064
Pretax Margin -24.677
Net Margin -23.992
Return on Assets -13.869
Return on Equity -34.766
Return on Total Capital -21.595
Return on Invested Capital -20.605

XRAY Capital Structure

Total Debt to Total Equity 116.993
Total Debt to Total Capital 53.916
Total Debt to Total Assets 39.492
Long-Term Debt to Equity 86.354
Long-Term Debt to Total Capital 39.796
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Dentsply Sirona Inc. - XRAY

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
4.23B 3.92B 3.96B 3.79B
Sales Growth
+26.60% -7.30% +1.10% -4.34%
Cost of Goods Sold (COGS) incl D&A
1.89B 1.79B 1.88B 1.82B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
346.00M 328.00M 343.00M 349.00M
Depreciation
124.00M 119.00M 132.00M 133.00M
Amortization of Intangibles
222.00M 209.00M 211.00M 216.00M
COGS Growth
+14.88% -5.29% +4.69% -2.72%
Gross Income
2.34B 2.13B 2.09B 1.97B
Gross Income Growth
+37.99% -8.94% -1.92% -5.79%
Gross Profit Margin
+55.28% +54.31% +52.69% +51.89%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.71B 1.76B 1.79B 1.74B
Research & Development
171.00M 174.00M 184.00M 165.00M
Other SG&A
1.54B 1.59B 1.61B 1.57B
SGA Growth
+20.54% +3.22% +1.76% -3.12%
Other Operating Expense
- - - -
-
Unusual Expense
(12.00M) 1.27B 386.00M 1.09B
EBIT after Unusual Expense
643.00M (904.00M) (91.00M) (859.00M)
Non Operating Income/Expense
(32.00M) (101.00M) (20.00M) (22.00M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
66.00M 50.00M 64.00M 55.00M
Interest Expense Growth
+6.45% -24.24% +28.00% -14.06%
Gross Interest Expense
66.00M 50.00M 64.00M 55.00M
Interest Capitalized
- - - -
-
Pretax Income
545.00M (1.05B) (175.00M) (936.00M)
Pretax Income Growth
+1,008.33% -293.58% +83.41% -434.86%
Pretax Margin
+12.88% -26.90% -4.41% -24.68%
Income Tax
134.00M (105.00M) (43.00M) (26.00M)
Income Tax - Current - Domestic
5.00M 5.00M 1.00M (5.00M)
Income Tax - Current - Foreign
154.00M 118.00M 86.00M 115.00M
Income Tax - Deferred - Domestic
12.00M (162.00M) 1.00M (62.00M)
Income Tax - Deferred - Foreign
(37.00M) (66.00M) (131.00M) (74.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
411.00M (950.00M) (132.00M) (910.00M)
Minority Interest Expense
- - - -
-
Net Income
411.00M (950.00M) (132.00M) (910.00M)
Net Income Growth
+595.18% -331.14% +86.11% -589.39%
Net Margin Growth
+9.71% -24.22% -3.33% -23.99%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
411.00M (950.00M) (132.00M) (910.00M)
Preferred Dividends
- - - -
-
Net Income Available to Common
411.00M (950.00M) (132.00M) (910.00M)
EPS (Basic)
1.8819 -4.4084 -0.6226 -4.4784
EPS (Basic) Growth
+597.07% -334.25% +85.88% -619.31%
Basic Shares Outstanding
218.40M 215.50M 212.00M 203.20M
EPS (Diluted)
1.8665 -4.4084 -0.6226 -4.4784
EPS (Diluted) Growth
+593.00% -336.19% +85.88% -619.31%
Diluted Shares Outstanding
220.20M 215.50M 212.00M 203.20M
EBITDA
977.00M 695.00M 638.00M 579.00M
EBITDA Growth
+59.64% -28.86% -8.20% -9.25%
EBITDA Margin
+23.09% +17.72% +16.09% +15.26%

Snapshot

Average Recommendation HOLD Average Target Price 12.75
Number of Ratings 18 Current Quarters Estimate 0.395
FY Report Date 03 / 2026 Current Year's Estimate 1.553
Last Quarter’s Earnings 0.277 Median PE on CY Estimate N/A
Year Ago Earnings 1.617 Next Fiscal Year Estimate 1.70
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 14 17 15
Mean Estimate 0.40 0.47 1.55 1.70
High Estimates 0.55 0.59 2.01 1.90
Low Estimate 0.28 0.36 1.15 1.40
Coefficient of Variance 18.19 16.18 11.47 7.09

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 3
OVERWEIGHT 1 1 1
HOLD 14 14 12
UNDERWEIGHT 0 0 0
SELL 1 1 0
MEAN Hold Hold Hold

Insider Actions for Dentsply Sirona Inc. - XRAY

Date Name Shares Transaction Value
Jan 14, 2026 Robert A. Johnson SVP, Chief Supply Chain Office 116,313 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Gregory T. Lucier Director 24,901 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Kevin J. Czerney VP, Chief Accounting Officer 3,493 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Brian T. Gladden Director 29,042 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Kevin J. Czerney VP, Chief Accounting Officer 28,041 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Michael J. Barber Director 17,945 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Andrea L. Frohning SVP, CHRO 1,759 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Andrea L. Frohning SVP, CHRO 34,002 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Janet S. Vergis Director 44,501 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Willie A. Deese Director 57,748 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Leslie F. Varon Director 57,541 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Clyde R. Hosein Director 41,253 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Jonathan J. Mazelsky Director 28,847 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Jonathan J. Mazelsky Director 14,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Daniel T. Scavilla President, CEO & Member of BOD; Director 17,945 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Kevin J. Czerney VP, Chief Accounting Officer 341 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Robert A. Johnson SVP, Chief Supply Chain Office 3,113 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 14, 2026 Betsy DeHaas Holden Director 54,614 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Daniel T. Scavilla President, CEO & Member of BOD; Director 1,102,600 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Gregory T. Lucier Director 82,301 Bona fide gift 0.00

Dentsply Sirona Inc. in the News